12.33
price up icon6.20%   0.72
pre-market  Pre-market:  11.77   -0.56   -4.54%
loading
Korro Bio Inc stock is traded at $12.33, with a volume of 107.27K. It is up +6.20% in the last 24 hours and down -4.34% over the past month. Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
See More
Previous Close:
$11.61
Open:
$11.7
24h Volume:
107.27K
Relative Volume:
0.61
Market Cap:
$177.83M
Revenue:
$6.39M
Net Income/Loss:
$-117.26M
P/E Ratio:
-0.9879
EPS:
-12.4807
Net Cash Flow:
$-79.08M
1W Performance:
+34.75%
1M Performance:
-4.34%
6M Performance:
+123.37%
1Y Performance:
-10.65%
1-Day Range:
Value
$11.69
$12.67
1-Week Range:
Value
$9.12
$12.67
52-Week Range:
Value
$5.2044
$55.89

Korro Bio Inc Stock (KRRO) Company Profile

Name
Name
Korro Bio Inc
Name
Phone
617-468-1999
Name
Address
60 FIRST STREET, CAMBRIDGE
Name
Employee
49
Name
Twitter
Name
Next Earnings Date
2026-05-06
Name
Latest SEC Filings
Name
KRRO's Discussions on Twitter

Compare KRRO vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
KRRO icon
KRRO
Korro Bio Inc
12.33 167.45M 6.39M -117.26M -79.08M -12.48
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
435.93 110.28B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
634.62 66.98B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
808.43 50.15B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
295.50 39.71B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
154.89 32.22B 742.00K -1.37B -1.07B -7.0731

Korro Bio Inc Stock (KRRO) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-13-26 Upgrade Raymond James Mkt Perform → Outperform
Feb-17-26 Upgrade William Blair Mkt Perform → Outperform
Jan-29-26 Upgrade Chardan Capital Markets Neutral → Buy
Jan-29-26 Upgrade H.C. Wainwright Neutral → Buy
Jan-29-26 Upgrade Piper Sandler Neutral → Overweight
Jan-28-26 Upgrade Cantor Fitzgerald Neutral → Overweight
Jan-28-26 Upgrade Oppenheimer Perform → Outperform
Nov-13-25 Downgrade Cantor Fitzgerald Overweight → Neutral
Nov-13-25 Downgrade Chardan Capital Markets Buy → Neutral
Nov-13-25 Downgrade H.C. Wainwright Buy → Neutral
Nov-13-25 Downgrade Piper Sandler Overweight → Neutral
Nov-13-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-13-25 Downgrade Raymond James Strong Buy → Mkt Perform
Nov-13-25 Downgrade William Blair Outperform → Mkt Perform
Apr-29-25 Initiated Cantor Fitzgerald Overweight
Apr-16-25 Initiated Chardan Capital Markets Buy
Jan-10-25 Initiated Oppenheimer Outperform
Oct-21-24 Initiated Raymond James Strong Buy
Aug-14-24 Initiated William Blair Outperform
Mar-28-24 Reiterated H.C. Wainwright Buy
Feb-27-24 Initiated BMO Capital Markets Outperform
Dec-04-23 Initiated H.C. Wainwright Buy
Nov-29-23 Initiated RBC Capital Mkts Outperform
Nov-10-23 Initiated Piper Sandler Overweight
Feb-15-23 Downgrade Chardan Capital Markets Buy → Neutral
Feb-13-23 Downgrade Cowen Outperform → Market Perform
Sep-22-21 Downgrade Goldman Buy → Neutral
Jan-27-21 Upgrade JP Morgan Neutral → Overweight
Dec-22-20 Initiated B. Riley Securities Buy
Jul-14-20 Initiated Oppenheimer Outperform
May-18-20 Downgrade JP Morgan Overweight → Neutral
Oct-28-19 Initiated Cowen Outperform
Oct-28-19 Initiated Goldman Buy
Oct-28-19 Initiated JP Morgan Overweight
View All

Korro Bio Inc Stock (KRRO) Latest News

pulisher
May 23, 2026

Korro Bio Stock Climbs Before Holiday; Bigger Test Still to Come - Bez Kabli

May 23, 2026
pulisher
May 21, 2026

Korro Bio Inc. (KRRO) Surges Nearly 12% as Biotech Momentum BuildsExpert Momentum Signals - Newser

May 21, 2026
pulisher
May 19, 2026

Korro Bio Selects KRRO-111 as RNA Editing Therapy Candidate for Alpha-1 Antitrypsin Deficiency (AATD) with Best-in-Class Preclinical Results 1 - Minichart

May 19, 2026
pulisher
May 19, 2026

Korro Bio, Inc.Common Stock (NQ: KRRO - The Chronicle-Journal

May 19, 2026
pulisher
May 19, 2026

Korro Bio adds AATD treatment candidate to pipeline By Investing.com - Investing.com South Africa

May 19, 2026
pulisher
May 19, 2026

H.C. Wainwright cuts Korro Bio stock price target on financing impact By Investing.com - Investing.com South Africa

May 19, 2026
pulisher
May 19, 2026

Korro Bio nominates new candidate for AATD - BioWorld News

May 19, 2026
pulisher
May 19, 2026

H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Cuts Target Price to $15 - Moomoo

May 19, 2026
pulisher
May 19, 2026

Korro Bio, Inc. selects KRRO-111 after preclinical success in repairing AAT protein - Traders Union

May 19, 2026
pulisher
May 19, 2026

H.C. Wainwright cuts Korro Bio stock price target on financing impact - Investing.com Nigeria

May 19, 2026
pulisher
May 19, 2026

Korro Bio Advances KRRO-111 for Alpha-1 Deficiency - TipRanks

May 19, 2026
pulisher
May 19, 2026

Korro Bio adds AATD treatment candidate to pipeline - Investing.com

May 19, 2026
pulisher
May 19, 2026

Citigroup initiates coverage of Korro Bio (KRRO) with buy recommendation - MSN

May 19, 2026
pulisher
May 18, 2026

KRRO Initiates Coverage by Citigroup -- Announces Buy Rating - GuruFocus

May 18, 2026
pulisher
May 18, 2026

Citi Initiates Korro Bio(KRRO.US) With Buy Rating, Announces Target Price $21 - Moomoo

May 18, 2026
pulisher
May 18, 2026

Lynx1 Capital Management LP's Korro Bio Inc(KRRO) Holding History - GuruFocus

May 18, 2026
pulisher
May 18, 2026

Citigroup Initiates Korro Bio at Buy With $21 Price Target - marketscreener.com

May 18, 2026
pulisher
May 16, 2026

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 16, 2026
pulisher
May 15, 2026

Should You Sell Korro Bio (KRRO) After -8.12% Drop? 2026-05-15Stock Picks - Newser

May 15, 2026
pulisher
May 15, 2026

Korro Bio, Inc. advances KRRO-121 RNA editing therapy for hyperammonemia toward clinical stage - Traders Union

May 15, 2026
pulisher
May 15, 2026

New Korro Bio hire gets option for 3,000 shares at $11.20 - Stock Titan

May 15, 2026
pulisher
May 14, 2026

TradingKey - TradingKey

May 14, 2026
pulisher
May 13, 2026

Korro Bio (KRRO) Price Target Decreased by 30.76% to 66.30 - MSN

May 13, 2026
pulisher
May 11, 2026

Korro announces oversubscribed $85 million private placement - MSN

May 11, 2026
pulisher
May 10, 2026

Number of shareholders of Korro Bio, Inc. – NASDAQ:KRRO - TradingView

May 10, 2026
pulisher
May 09, 2026

Korro Bio (NASDAQ:KRRO) Announces Quarterly Earnings Results - MarketBeat

May 09, 2026
pulisher
May 08, 2026

Wave Life Sciences (WVE) Attracts Positive Attention Amid Compet - GuruFocus

May 08, 2026
pulisher
May 08, 2026

JonesTrading Upgrades Korro Bio(KRRO.US) to Buy Rating, Announces Target Price $23 - Moomoo

May 08, 2026
pulisher
May 08, 2026

Jones Trading upgrades Korro Bio stock rating on AATD program potential By Investing.com - Investing.com South Africa

May 08, 2026
pulisher
May 08, 2026

Jones Trading upgrades Korro Bio stock rating on AATD program potential - Investing.com Nigeria

May 08, 2026
pulisher
May 08, 2026

Chardan Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15 - Moomoo

May 08, 2026
pulisher
May 07, 2026

Korro Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 07, 2026
pulisher
May 07, 2026

Korro Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 07, 2026
pulisher
May 07, 2026

Korro Bio IncReports No Collaboration Reve - Moomoo

May 07, 2026
pulisher
May 07, 2026

Korro Bio (KRRO) trims R&D spend and boosts cash to $157M - Stock Titan

May 07, 2026
pulisher
May 07, 2026

Korro Bio, Inc. 1Q 2026: Revenue $0M, EPS $(1.69) — 10-Q Summary - TradingView

May 07, 2026
pulisher
May 07, 2026

Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times

May 07, 2026
pulisher
May 07, 2026

Korro raises $85M, targets 2026 filing for rare-disease drug - Stock Titan

May 07, 2026
pulisher
May 07, 2026

Korro Bio (Nasdaq: KRRO) boosts cash to $157M and targets 2026 KRRO-121 filing - Stock Titan

May 07, 2026
pulisher
May 06, 2026

What Korro Bio (KRRO) management is not saying enough about (Technical Strength) 2026-05-06Top Trending Breakouts - newser.com

May 06, 2026
pulisher
May 05, 2026

Korro CEO and top executives line up two investor fireside chats - Stock Titan

May 05, 2026
pulisher
May 05, 2026

Korro to Participate in Upcoming Investor Conferences - marketscreener.com

May 05, 2026
pulisher
May 05, 2026

Korro Bio executives to present at two major investor conferences in May 2026 - Pluang

May 05, 2026
pulisher
May 01, 2026

Korro Bio Inc expected to post a loss of $1.84 a shareEarnings Preview - TradingView

May 01, 2026
pulisher
Apr 30, 2026

What makes Korro Bio, Inc. (KRRO) a new buy stock - MSN

Apr 30, 2026
pulisher
Apr 29, 2026

Korro Bio (KRRO) to Release Quarterly Earnings on Wednesday - MarketBeat

Apr 29, 2026
pulisher
Apr 28, 2026

What Makes Korro Bio, Inc. (KRRO) a New Buy Stock - Yahoo Finance Australia

Apr 28, 2026

Korro Bio Inc Stock (KRRO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Korro Bio Inc Stock (KRRO) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Yang Rick
10% Owner
Mar 10 '26
Buy
11.11
207,100
2,300,881
1,297,893
SANDELL SCOTT D
10% Owner
Mar 10 '26
Buy
11.11
207,100
2,300,881
1,297,893
New Enterprise Associates 17,
10% Owner
Mar 10 '26
Buy
11.11
207,100
2,300,881
1,297,893
Chang Carmen
10% Owner
Mar 10 '26
Buy
11.11
207,100
2,300,881
1,297,893
BASKETT FOREST
10% Owner
Mar 10 '26
Buy
11.11
207,100
2,300,881
1,297,893
Mathers Edward T
10% Owner
Mar 10 '26
Buy
11.11
207,100
2,300,881
1,297,893
Makhzoumi Mohamad
10% Owner
Mar 10 '26
Buy
11.11
207,100
2,300,881
1,297,893
Walker Paul Edward
10% Owner
Mar 10 '26
Buy
11.11
207,100
2,300,881
1,297,893
Florence Anthony A. Jr.
10% Owner
Mar 10 '26
Buy
11.11
207,100
2,300,881
1,297,893
$29.66
price down icon 0.98%
$92.25
price up icon 0.12%
$108.87
price up icon 2.48%
$53.86
price down icon 1.17%
ONC ONC
$302.44
price down icon 2.52%
$154.89
price up icon 2.20%
Cap:     |  Volume (24h):